Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of BAY 43-9006 [sorafenib] in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)

Trial Profile

A Phase II Study of BAY 43-9006 [sorafenib] in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Bladder cancer; Pelvic cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Jul 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top